Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Definium Therapeutics ( (DFTX) ) has issued an announcement.
On January 28, 2026, Definium Therapeutics, Inc. expanded its board of directors from six to seven members and appointed Roger Adsett to the newly created seat, with his term effective January 29, 2026 and running until the company’s 2026 annual general meeting or until a successor is chosen. Adsett, who was not assigned to any board committees at the time of appointment, will receive annual cash compensation of $40,000 under the company’s non-employee director compensation policy and an option to purchase 50,000 common shares that vests over time subject to his continued board service, reflecting a standard governance and incentive structure with no related-party arrangements or disclosable transactions reported in connection with his selection.
The most recent analyst rating on (DFTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Definium Therapeutics stock, see the DFTX Stock Forecast page.
Spark’s Take on DFTX Stock
According to Spark, TipRanks’ AI Analyst, DFTX is a Neutral.
The score is held back mainly by weak financial performance (no revenue, sizeable ongoing losses, and heavy cash burn), partially offset by a stronger near-term setup from the earnings call (financing runway and clear Phase III catalysts) and supportive technical momentum. Valuation remains challenging due to negative earnings and no dividend support.
To see Spark’s full report on DFTX stock, click here.
More about Definium Therapeutics
Average Trading Volume: 2,122,014
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.72B
See more insights into DFTX stock on TipRanks’ Stock Analysis page.